indiabrand.org 
Empagliflozin is marketed under the brand name Jardiance in India. This medication is prescribed for managing type 2 diabetes mellitus by promoting glucose excretion through the urine. Jardiance helps in improving glycemic control and may also contribute to weight loss. Available in various dosages, this SGLT2 inhibitor is commonly included in treatment plans alongside lifestyle modifications for better diabetes management.
Brands to consider
Jardiance
Jardiance is a prominent brand of empagliflozin widely recognized in India for managing type 2 diabetes effectively. This medication works by inhibiting sodium-glucose co-transporter 2 (SGLT2), leading to reduced blood sugar levels and improved glycemic control. It also offers benefits such as weight loss and a lower risk of cardiovascular events. Individuals with type 2 diabetes in India may find Jardiance a suitable option due to its efficacy and potential to positively impact their overall health.
Glyxambi
Glyxambi combines empagliflozin and linagliptin, targeting Type 2 diabetes management effectively. The dual-action mechanism helps improve glycemic control while reducing cardiovascular risks. Glyxambi benefits patients with both high blood sugar and a need for weight management, fitting diverse treatment needs. Healthcare providers in India often recommend this brand for its proven efficacy and safety profile, integrating well into comprehensive diabetes care plans. Your healthcare consultation can provide more tailored insights on incorporating Glyxambi into your treatment strategy.
Synjardy
Synjardy is a prescription medication that combines empagliflozin with metformin, specifically designed for managing type 2 diabetes in India. This brand is notable for its ability to lower blood sugar levels effectively while also providing cardiovascular benefits. With a unique formulation, Synjardy may aid in weight management, making it a comprehensive option for individuals seeking control over their diabetes and overall health. Patients should consult healthcare professionals to determine if Synjardy aligns with their treatment plan.
Trajenta Duo
Trajenta Duo offers a combination of linagliptin and empagliflozin, effective for managing type 2 diabetes in India. This formulation helps improve glycemic control while providing cardiovascular benefits. Clinical studies show a reduction in HbA1c levels, making Trajenta Duo a viable option for those seeking to enhance their diabetes management. Your healthcare provider may recommend this brand based on individual health needs and treatment goals.
Empagliflozin Metformin
Empagliflozin Metformin offers a dual-action approach to managing type 2 diabetes through its combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and metformin, a biguanide. This formulation can help improve glycemic control by reducing glucose reabsorption in the kidneys while simultaneously increasing insulin sensitivity. Many patients in India may benefit from the reduced risk of cardiovascular events associated with empagliflozin. With a growing emphasis on diabetes management, your healthcare provider may consider this combination therapy for its potential effectiveness and safety profile.
Therapeutic Category
Empagliflozin, marketed under the brand name Jardiance in India, falls under the therapeutic category of SGLT2 inhibitors. This medication is primarily used in the management of type 2 diabetes, aiding in blood sugar control. Jardiance works by preventing glucose reabsorption in the kidneys, promoting its excretion through urine. It may also benefit patients with heart failure and chronic kidney disease. Your healthcare provider can offer insights into its use and potential benefits for your specific condition.
Mechanism of Action
Empagliflozin, marketed under the brand name Jardiance in India, operates as an SGLT2 inhibitor. It works by blocking the sodium-glucose cotransporter 2 in the kidneys, which leads to reduced reabsorption of glucose and increased glucose excretion in urine. This process helps lower blood glucose levels in patients with type 2 diabetes. Empagliflozin also has cardiovascular benefits by reducing the risk of cardiovascular events in individuals with type 2 diabetes and existing heart disease. Your healthcare provider may consider this medication as part of a comprehensive diabetes management plan.
FDA Approval Status
Empagliflozin, marketed under the brand name Jardiance, has received FDA approval in the United States for the treatment of type 2 diabetes. In India, it is also recognized for managing blood sugar levels in diabetic patients. The approval process for such medications is regulated by the Central Drugs Standard Control Organization (CDSCO) in India. Users should verify the most current status and prescription details with healthcare professionals or reliable medical sources.
Market Competitors
In India, the primary competitors for empagliflozin include brands like Canagliflozin by Janssen Pharmaceuticals and Dapagliflozin offered by AstraZeneca. Both alternatives target similar patient demographics dealing with type 2 diabetes. These medications work by inhibiting sodium-glucose co-transporter 2 (SGLT2), promoting glucose excretion through urine. Your healthcare provider may suggest these options based on individual treatment needs.
Patient Demographics
Empagliflozin, marketed under the brand name Jardiance in India, is primarily prescribed for adults with type 2 diabetes. Your patient demographics typically include individuals aged 45 and above, with a higher prevalence observed in urban populations due to lifestyle factors. Data indicates a significant proportion of male patients, particularly in regions with high obesity rates, influencing the need for glucose-lowering therapies. Moreover, the increase in cardiovascular risk among these patients underscores the demand for effective management options in diabetes care.